S&P 500   3,382.37 (+1.46%)
DOW   27,957.08 (+0.98%)
QQQ   272.44 (+2.73%)
AAPL   452.45 (+3.42%)
MSFT   209.95 (+3.23%)
FB   261.47 (+2.08%)
GOOGL   1,509.17 (+1.93%)
AMZN   3,164.26 (+2.71%)
NVDA   457.48 (+5.41%)
CGC   17.27 (+1.89%)
BABA   255.54 (+2.87%)
TSLA   1,566.14 (+13.95%)
GE   6.63 (-1.49%)
MU   48.57 (+1.70%)
AMD   82.16 (+6.87%)
T   30.21 (+0.03%)
F   7.09 (-1.94%)
ACB   9.81 (-2.10%)
GILD   68.90 (+1.17%)
NFLX   479.55 (+2.70%)
DIS   131.73 (+0.95%)
BAC   26.76 (-0.59%)
BA   175.53 (-2.55%)
S&P 500   3,382.37 (+1.46%)
DOW   27,957.08 (+0.98%)
QQQ   272.44 (+2.73%)
AAPL   452.45 (+3.42%)
MSFT   209.95 (+3.23%)
FB   261.47 (+2.08%)
GOOGL   1,509.17 (+1.93%)
AMZN   3,164.26 (+2.71%)
NVDA   457.48 (+5.41%)
CGC   17.27 (+1.89%)
BABA   255.54 (+2.87%)
TSLA   1,566.14 (+13.95%)
GE   6.63 (-1.49%)
MU   48.57 (+1.70%)
AMD   82.16 (+6.87%)
T   30.21 (+0.03%)
F   7.09 (-1.94%)
ACB   9.81 (-2.10%)
GILD   68.90 (+1.17%)
NFLX   479.55 (+2.70%)
DIS   131.73 (+0.95%)
BAC   26.76 (-0.59%)
BA   175.53 (-2.55%)
S&P 500   3,382.37 (+1.46%)
DOW   27,957.08 (+0.98%)
QQQ   272.44 (+2.73%)
AAPL   452.45 (+3.42%)
MSFT   209.95 (+3.23%)
FB   261.47 (+2.08%)
GOOGL   1,509.17 (+1.93%)
AMZN   3,164.26 (+2.71%)
NVDA   457.48 (+5.41%)
CGC   17.27 (+1.89%)
BABA   255.54 (+2.87%)
TSLA   1,566.14 (+13.95%)
GE   6.63 (-1.49%)
MU   48.57 (+1.70%)
AMD   82.16 (+6.87%)
T   30.21 (+0.03%)
F   7.09 (-1.94%)
ACB   9.81 (-2.10%)
GILD   68.90 (+1.17%)
NFLX   479.55 (+2.70%)
DIS   131.73 (+0.95%)
BAC   26.76 (-0.59%)
BA   175.53 (-2.55%)
S&P 500   3,382.37 (+1.46%)
DOW   27,957.08 (+0.98%)
QQQ   272.44 (+2.73%)
AAPL   452.45 (+3.42%)
MSFT   209.95 (+3.23%)
FB   261.47 (+2.08%)
GOOGL   1,509.17 (+1.93%)
AMZN   3,164.26 (+2.71%)
NVDA   457.48 (+5.41%)
CGC   17.27 (+1.89%)
BABA   255.54 (+2.87%)
TSLA   1,566.14 (+13.95%)
GE   6.63 (-1.49%)
MU   48.57 (+1.70%)
AMD   82.16 (+6.87%)
T   30.21 (+0.03%)
F   7.09 (-1.94%)
ACB   9.81 (-2.10%)
GILD   68.90 (+1.17%)
NFLX   479.55 (+2.70%)
DIS   131.73 (+0.95%)
BAC   26.76 (-0.59%)
BA   175.53 (-2.55%)
Log in

NASDAQ:NOVNNovan Stock Price, Forecast & News

$0.57
-0.05 (-8.39 %)
(As of 08/12/2020 02:49 PM ET)
Add
Compare
Today's Range
$0.56
Now: $0.57
$0.63
50-Day Range
$0.47
MA: $0.62
$1.23
52-Week Range
$0.22
Now: $0.57
$3.72
Volume264,879 shs
Average Volume16.51 million shs
Market Capitalization$45.06 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.06
Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. has a strategic alliance with Orion Corporation to manufacture topical nitric oxide-releasing product candidates. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Read More
Novan logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NOVN
CUSIPN/A
Phone919-485-8080

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.90 million
Book Value($0.89) per share

Profitability

Net Income$-30,640,000.00
Net Margins-594.59%

Miscellaneous

Employees47
Market Cap$45.06 million
Next Earnings DateN/A
OptionableNot Optionable
$0.57
-0.05 (-8.39 %)
(As of 08/12/2020 02:49 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novan (NASDAQ:NOVN) Frequently Asked Questions

How has Novan's stock been impacted by COVID-19 (Coronavirus)?

Novan's stock was trading at $0.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NOVN shares have increased by 9.6% and is now trading at $0.5701.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Novan?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Novan
.

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) released its earnings results on Wednesday, May, 20th. The company reported ($0.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.21 million for the quarter.
View Novan's earnings history
.

What price target have analysts set for NOVN?

2 equities research analysts have issued 1 year target prices for Novan's shares. Their forecasts range from $0.50 to $1.50. On average, they anticipate Novan's share price to reach $1.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price.
View analysts' price targets for Novan
.

Has Novan been receiving favorable news coverage?

Media stories about NOVN stock have trended negative on Wednesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novan earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Novan
.

Are investors shorting Novan?

Novan saw a decrease in short interest in February. As of February 15th, there was short interest totaling 186,100 shares, a decrease of 53.4% from the January 31st total of 399,500 shares. Based on an average trading volume of 550,700 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.0% of the shares of the stock are sold short.
View Novan's Short Interest
.

Who are some of Novan's key competitors?

What other stocks do shareholders of Novan own?

Who are Novan's key executives?

Novan's management team includes the following people:
  • Mr. G. Kelly Martin, CEO & Director (Age 60)
  • Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)
  • Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)
  • Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)
  • Dr. Carri Geer, Sr. VP & CTO

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

Who are Novan's major shareholders?

Novan's stock is owned by many different institutional and retail investors. Top institutional shareholders include UBS Group AG (0.25%). Company insiders that own Novan stock include G Kelly Martin, John M Gay, John W Palmour, Life Sciences Holdings L Malin, Paula B Stafford and Robert Alexander Ingram.
View institutional ownership trends for Novan
.

Which institutional investors are buying Novan stock?

NOVN stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Novan stock in the last two years include G Kelly Martin, John M Gay, John W Palmour, Paula B Stafford, and Robert Alexander Ingram.
View insider buying and selling activity for Novan
.

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $0.57.

How big of a company is Novan?

Novan has a market capitalization of $45.23 million and generates $4.90 million in revenue each year. The company earns $-30,640,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Novan employs 47 workers across the globe.

What is Novan's official website?

The official website for Novan is www.novan.com.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.